Bajaj Healthcare Q2 FY27 Profit Rises 27% on Sales Growth
Key highlights
- Bajaj Healthcare’s Q2 FY27 standalone net profit increased 26.8% year-on-year to ₹14.09 crore.
- Revenue from operations rose 18.9% year-on-year to ₹175.90 crore in Q2 FY27.
- API exports grew 28.5% year-on-year and formulations revenue increased 82% during Q2 FY27.
- India Ratings & Research upgraded Bajaj Healthcare’s long-term credit rating to IND A/Stable.
powered by IRIS

Quarterly performance at a glance
Know Bajaj Healthcare inside out
Results, valuation, peers and who's buying, in one view.
Bajaj Healthcare Ltd reported higher revenue and profit for the second quarter of FY27, with growth across its standalone operations. Revenue from operations for the quarter ended September 30, 2026 rose 18.9% year-on-year to ₹175.90 crore. Standalone total income increased 18.2% to ₹176.79 crore from ₹149.57 crore in the corresponding quarter of FY26. Net profit grew 26.8% to ₹14.09 crore, compared with ₹11.11 crore a year earlier. The result also showed sequential improvement from the June quarter. Total income was 6.2% above the ₹166.44 crore reported in Q1 FY27. Net profit was 2.8% higher than ₹13.70 crore in the preceding quarter.
Earnings per share improves
Basic earnings per share rose to ₹4.19 in Q2 FY27 from ₹3.53 in Q2 FY26. This represented year-on-year growth of 18.7%. EPS was also above ₹4.07 in Q1 FY27. The increase in profit was faster than the rise in total income on a year-on-year basis. However, quarterly earnings should be viewed alongside changes in operating and tax costs. The company reported a tax charge equivalent to 22.2% of profit before tax, against 15.6% in the June quarter. This higher tax incidence was one of the factors relevant to comparing quarterly profitability.
Margins show mixed movement
The standalone net profit margin stood at 7.97% in Q2 FY27. It improved from 7.43% in the year-ago period but declined from 8.23% in Q1 FY27. The reported operating profit margin was 17.74% for the September quarter. That was 48 basis points below 18.22% in Q2 FY26, while improving by 38 basis points from 17.36% in Q1 FY27. The company reported EBITDA of ₹32.1 crore for the quarter, up 12.2% year-on-year. The figures indicate that revenue expansion continued even as operating profitability remained below the year-ago level.
Key standalone financial data
Half-year results remain higher
For the first half of FY27, Bajaj Healthcare reported revenue of ₹341.5 crore, up 15.1% from the corresponding period of the previous financial year. Profit after tax for the half year increased 21.1% to ₹27.8 crore. The half-year figures provide context for the September-quarter performance, showing growth across both the first and second quarters. The company’s quarterly revenue growth was stronger than its reported first-half revenue growth rate. Its September-quarter profit growth was also ahead of the half-year PAT growth rate. The reported numbers are standalone figures and should be read accordingly when assessing the business.
Got a follow-up? Ask IRIS
API exports and formulations contribute
Bajaj Healthcare said API exports grew 28.5% year-on-year during the period. It also reported an 82% year-on-year increase in formulations revenue. The company cited the launch of Cenobamate API and tablets in India as a business development during the quarter. Commercial launch of the product began in September 2026. These updates accompanied the company’s financial results for Q2 and H1 FY27. The export and formulations data indicate contributions from more than one operating segment. The results announcement did not provide a separate revenue amount for each of these business lines.
Credit rating update
India Ratings & Research upgraded Bajaj Healthcare’s long-term credit rating to IND A/Stable. The rating update was disclosed alongside the Q2 FY27 results. A long-term rating reflects the credit assessor’s view of an issuer’s capacity to meet financial obligations. The Stable outlook forms part of the reported rating designation. The results material did not quantify any direct financial impact of the rating change. Investors can therefore separate the rating action from the company’s reported quarterly income and profit figures.
Earnings call recording made available
Bajaj Healthcare held its Q2 FY27 earnings call on October 19, 2026, at 5 PM IST. The company subsequently informed investors that an audio recording of the call had been made available on its website through a direct link. The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements regulations. It followed the company’s earlier notice dated October 14 regarding the earnings call. The availability of the recording allows shareholders and other market participants to access the discussion after the live event. The company’s disclosure relates to the audio recording rather than an earnings-call transcript.
What the figures mean for investors
The September-quarter result shows that Bajaj Healthcare increased standalone revenue, net profit and EPS from both a year earlier and the preceding quarter. Revenue from operations grew by ₹28.00 crore year-on-year, while net profit increased by ₹2.98 crore. At the same time, the net profit margin declined sequentially and operating margin was lower than the year-ago quarter. This makes cost and margin trends relevant alongside the reported sales growth. API export growth, higher formulations revenue and the Cenobamate launch were the operational updates disclosed with the results. The IND A/Stable rating upgrade and earnings-call recording add to the information available to investors following the quarterly announcement.
Conclusion
Bajaj Healthcare closed Q2 FY27 with standalone total income of ₹176.79 crore and net profit of ₹14.09 crore. The company has made the October 19 earnings-call audio available on its website, allowing investors to review management’s discussion of the quarter and the reported business updates.


